DOCSLIB.ORG

2019 Proceedings ACVO 50Th Annual Conference & Trade Show

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2019 Proceedings ACVO 50Th Annual Conference & Trade Show 2019 Proceedings ACVO 50th Annual Conference & Trade Show AMERICAN COLLEGE OF VETERINARY OPHTHALMOLOGISTS PO Box 1311 Meridian, Idaho 83680 Phone: 208-466-7624 | Fax: 208-895-7872 E-mail: [email protected] Innovation that inspires. • Foldable IOLs • Bandage Lenses • Viscoelastic Solutions • CTRs • Stellaris Elite™ • Reusable and Single-Use Instruments vision enhancement system Contact Us to Schedule a Demo (800) 338-2020 bauschandlombvet.com Stellaris Elite is a trademark of Bausch & Lomb Incorporated or its affiliates. © Bausch & Lomb Incorporated. SRG.0103.USA.18 Thank You 2019 Sponsors! PLATINUM - $7,500+ GOLD - $5,000-$7,499 SILVER - $2,500-$4,999 BRONZE - $1,500-$2,499 GENERAL - up to $1,499 PACK LEADER DVM | OCUSCIENCE 2019 Proceedings Notes i Table of Contents Welcome from Planning Committee Chair .................................................................................. iii - iv Pioneering a Vision.................................................................................................................. v Conference Schedule.................................................................................................................. vi-vii Thank you................................................................................................................................... viii Conference Information & Schedule Notes.................................................................................. ix Meeting Space Maps................................................................................................................... x Keynote Speaker.......................................................................................................................... xi Teaching and Learning Meeting.................................................................................................... xii General Practitioners’ Course....................................................................................................... xiii Vitreous Society Meeting.............................................................................................................. xiv Presenter Schedules Thursday General Sessions......................................................................................................... xv-xvi Thursday Exotics Sessions........................................................................................................... xvi Friday Posters............................................................................................................................... xvii-xviii Friday General Sessions............................................................................................................... xix Saturday Posters........................................................................................................................... xx-xxi Saturday General Sessions........................................................................................................... xxii Rememberance of Passed Members............................................................................................ xxiii Exhibitors Exhibitor Products & Services Cross-Reference Guide............................................................... xxiv Exhibitor Floor Plan..................................................................................................................... xxvi Exhibitor & Sponsor Information.................................................................................................. xxvii Abstracts In-Depth Session Lecture Notes................................................................................................. 1-8 Thursday General Session Abstracts.......................................................................................... 9-27 In-Depth Exotics Session Lecture Notes..................................................................................... 28-31 Thursday Exotics Sessions....................................................................................................... 32-41 Friday Poster Abstracts............................................................................................................... 42-76 Friday General Session Abstracts................................................................................................ 77-93 Friday Vitreous Society Abstracts........................................................................................... 94-102 Saturday Poster Abstracts............................................................................................................ 103-137 Saturday General Session Abstracts........................................................................................... 138-158 Notes/Advertisements.................................................................................................................. 159-209 Dr. Anne Gemensky- Metzler Dr. Dineli Bras, Chair Dr. Wendy Townsend ii Welcome to the 50th Annual Conference of the American College of Veterinary Ophthalmologists Dear ACVO Conference Attendee, Welcome to the 2019 ACVO Annual Conference in Hawaii. This year we celebrate our 50th Anniversary in Maui, the second largest Hawaiian island, where you will find over 120 miles of pristine red, black and white sandy beaches. Take the time to explore the breathtaking landscapes of Haleakala, go hiking, or simply relax by the beach. Maui has set the stage with one of the most beautiful natural backdrops for our extraordinary scientific program, collaborative presentations, and the celebration of our college’s history. We have a very exciting meeting where we will experience how experts in different fields join together to collaborate and provide phenomenal presentations. The solid scientific program boasts 65 oral presentations and 68 posters. Once again, we have invited “In-Depth” speakers to headline the opening day at 8 am. Drs. Cameron Whittaker and Gladys Boo will co-present a 50-minute presentation on Advanced Corneal Endothelial Transplantation; DSEK and DMEK, followed by an excellent series of corneal abstract presenters. We will also host a concurrent exotics scientific session Thursday after lunch. The planning committee is ecstatic to have Dr. Claire Simeone, the first veterinarian selected as a TED fellow, and veterinarian to the world’s largest marine mammal rehabilitation hospital, as the “In Depth” speaker leading this session at 1:30 pm. Note that these sessions will be recorded so that you may view them post conference. For a long time, I have envisioned honoring our mentors and founding fathers of our college. What a better time to celebrate our career’s roots and recognize the ones who paved the road of excellence for our college during our 50th ACVO Anniversary. During the conference, we will host a founder’s presentation and film event, ‘Pioneering a Vision, Honoring ACVO’s Founders and History’, where we will share with you a historical documentary that will unveil our College’s history told by our own founding fathers. It is an honor to be part of this project and I would like to thank Dr. Phil Pickett and his son, Matthew Pickett, for pouring out their hearts and passion in making this a reality. This would have not been possible without the help of Drs. Wendy Townsend, Terah Webb, our founding fathers and all our members who participated in this film. We would like you to join us in recognizing their valued contributions and celebrate with them how they have brightened our future. We want them to know you are part of this event so we will have a place for you to share a note of gratitude on the impact they have made. Make sure you take the time to write a note, we will share it with them in a special way. You cannot miss the Keynote presentation on how making mistakes and self-forgiveness can influence the surgical outcome and well-being of our patients. Drs. Chris Murphy, Sara Thomasy, Nandini Gandhi, and Mark J. Mannis are our Keynote Lecturers on ‘Making Mistakes: “The Importance of Forgiveness”. This team of experts in veterinary and human ophthalmology will provide our residents and interns an excellent Residents’ Workshop on fundamentals of microsurgery. This program will be recorded should any of our Diplomates wish to access this material as well. Thank you to Drs. Chris Murphy, Sara Thomasy, Nandini Gandhi, and Mark J. Mannis for their collaborative efforts on these presentations. We would also like to thank our course organizers, Dr. Margie Gilmour for the Teaching and Learning Meeting, Dr. Joe Wolfer for the Vitreous Society Meeting, and Dr. Wendy Townsend for the General Practitioners Course. Dr. Wendy Townsend has lined up wonderful speakers for our General Practitioners’ Course on Saturday. Special thanks to our speakers and fellow ACVO Members: Drs. Kathy Good, Stephanie Beaumont, Gia Klauss, Holly Hamilton, Kate Myrna, and Gil Ben-Shlomo. Returning this year, the ‘ACVO Career Fair’ will take place on Thursday during lunch time, 12-1:30pm. The Career Fair is a member benefit (the opportunity to host a table).The fair is complimentary for residency and training programs to present, and will provide all attendees a connection point for those seeking a residency, internship, or DVM position with member diplomates who are seeking to fill such positions. Conference attendees will find ‘table-hosts’ via a table marker and map to facilitate identify the point of interest. Make sure to check out the detailed position descriptions hosted in the ‘on-site’ tab on the conference
Load more

Recommended publications
  • Anxiety Disorders of Childhood and Adolescence Jesse C
    Anxiety Disorders of Childhood and Adolescence Jesse C. Rhoads, DO & Craig L. Donnelly, MD 1. Background, EpidEmiology and rElEvancE Anxiety symptoms are ubiquitous in youth. Clinicians need to be familiar with the normal developmental course of anxieties in youth and their consequent mastery by children in order to differentiate normative versus pathological anxiety. Anxiety symptoms do not necessarily constitute an anxiety disorder. Fear and anxiety are common experiences across childhood and adolescence. The clinician evaluating childhood anxiety disorders faces the task of differentiating the normal, transient and developmentally appropriate expressions of anxiety from pathological anxiety. Adept assessment and management of anxiety symptoms through reassurance, anticipatory guidance and psychoeducation of parents may forestall the development of full blown anxiety syndromes. Anxiety disorders are among the most common psychiatric disorders in children and adolescents affecting from 7-15% of individuals under 18 years of age. Anxiety disorders are not rare and often mimic or are comorbid with other childhood disorders. Symptoms such as school refusal, tantrums, or irritability may be less reflective of oppositional behavior than an underlying social phobia or generalized anxiety disorder. Given the uniqueness of each child and the complex interplay among the internal and external variables that drive anxiety, a multimodal approach to diagnosis and treatment is warranted. Anxiety disorders are a heterogeneous group of disorders that vary in their etiology, treatment, and prognosis. Given these differences, we will discuss each condition individually to help the primary care clinician in parsing out the necessary details of each disorder. Separation anxiety disorder The estimated prevalence of SAD is 4-5%, making it one of the most common childhood psychiatric disorders.
    [Show full text]
  • Addison's Disease Elucidating PANDAS
    PRACTICE BUILDING Naturopathic Specialty Practice: Keys to NATUROPATHIC DOCTOR NEWS & REVIEW Making It Successful ..........................>>10 Darin Ingels, ND VOLUME 10 ISSUE 4 April 2014 | Autoimmune / ALLER gy Medicine Sometimes specialty practices happen by accident. A case study and some tips help pave the way for Tolle Causam success. TOLLE CAUSAM Autoimmunity and the Gut: Elucidating PANDAS How Intestinal Inflammation Contributes to Autoimmune Disease .....................>>12 Follow-Up Discussion of an Immune-Mediated Jenny Berg, ND, LAc Kelly Baker, ND, LAc Intestinal flora influences our immune system’s Mental Illness ability to differentiate self from non-self. Steven Rondeau, ND, BCIA-EEG VIS MEDICATRIX NATURAE Allergy Elimination Technique: Simplified ANDAS is an acronym for “Pediatric Treatment of Difficult Cases ..............>>15 PAutoimmune Neuropsychiatric Sheryl Wagner, ND Disorder Associated with Streptococcus.” A few case studies illustrate the surprisingly broad This condition, which was initially application of NAET with patients. identified by Sue Swedo, MD, and DOCERE described in the American Journal of Autoimmune Infertility in Women: Psychiatry in 1998,1 is characterized by Part 2 ...................................................>>16 abrupt-onset obsessive-compulsive Fiona McCulloch, BSc, ND disorder (OCD) and/or other Intestinal support, autoimmune diet, and neuropsychiatric symptoms in a child. (See nutraceuticals help reverse a common cause of Table 1 for Swedo’s original diagnostic female infertility. criteria.) In my previous NDNR paper NATUROpaTHIC NEWS from 2010,2 I described the presentation, history and controversy surrounding this Association Spotlight: An Introduction newly identified syndrome. Since that to the ANRI and NORI .........................>>20 time, several other groups have sought Colleen Huber, NMD to better redefine this condition, and the Dr Huber introduces ANRI & NORI, organizations committed to the advancement of research & acronym, PANS, or Pediatric Acute-Onset education on chronic disease.
    [Show full text]
  • Ageing in Dogs (Canis Familiaris) and Its Relationship to Their Environment
    AGEING IN DOGS (CANIS FAMILIARIS) AND ITS RELATIONSHIP TO THEIR ENVIRONMENT LUÍSA MASCARENHAS LADEIA DUTRA PhD Thesis 2019 Ageing in dogs (Canis Familiaris) and its rela- tionship to their environment Luísa Mascarenhas Ladeia Dutra This thesis is presented to the School of Environmental & Life Science, University of Salford, in fulfilment of the requirements for the degree of Ph.D. Supervised by Professor Robert J. Young Co-supervised by Professor Jean Phillippe Boubli March 2019 Table of contents Chapter 1 General Introduction ......................................................................... 19 1.1 Animal Welfare Assessment ................................................................... 19 1.2 Evaluation of stress levels as a measure of animal welfare .................... 21 1.3 Telomeres as biological clocks ................................................................ 25 1.4 Apparent age as a measure of life experience ........................................ 29 1.5 Canids as a model group ........................................................................ 31 1.6 Thesis structure ....................................................................................... 32 Chapter 2 Validating the use of oral swabs for telomere length assessment in dogs 34 2.1 Introduction ............................................................................................. 34 2.2 Objective ................................................................................................. 37 2.3 Justification ............................................................................................
    [Show full text]
  • Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients with Elevated Intraocular
    Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2) JANET B. SERLE, L. JAY KATZ, EUGENE MCLAURIN, THERESA HEAH, NANCY RAMIREZ-DAVIS, DALE W. USNER, GARY D. NOVACK, AND CASEY C. KOPCZYNSKI, FOR THE ROCKET-1 AND ROCKET-2 STUDY GROUPS PURPOSE: To evaluate the efficacy and ocular and sys- ROCKET-2) for timolol (P < .0001 for netarsudil vs temic safety of netarsudil 0.02% ophthalmic solution, a timolol). rho-kinase inhibitor and norepinephrine transporter in- CONCLUSIONS: In 2 large, randomized, double-masked hibitor, in patients with open-angle glaucoma and ocular trials reported here, once-daily dosing of netarsudil hypertension. 0.02% was found to be effective and well tolerated for DESIGN: Double-masked, randomized noninferiority the treatment of patients with ocular hypertension and clinical trials: Rho Kinase Elevated IOP Treatment Trial open-angle glaucoma. The novel pharmacology and 1 and 2 (ROCKET-1 and ROCKET-2). aqueous humor dynamic effects of this molecule suggest METHODS: After a washout of all pre-study ocular hy- it may be a useful addition to the armamentarium of potensive medications, eligible patients were randomized ocular hypotensive medications. (Am J Ophthalmol to receive netarsudil 0.02% once daily (q.d.), timolol 2018;186:116–127. Ó 2017 The Authors. Published 0.5% twice a day (b.i.d.), and (ROCKET-2 only) netar- by Elsevier Inc. This is an open access article under the sudil 0.02% b.i.d.
    [Show full text]
  • Table 1. Glaucoma Medications: Mechanisms, Dosing and Precautions Brand Generic Mechanism of Action Dosage/Avg
    OPTOMETRIC STUDY CENTER Table 1. Glaucoma Medications: Mechanisms, Dosing and Precautions Brand Generic Mechanism of Action Dosage/Avg. % Product Sizes Side Effects Warnings Reduction CHOLINERGIC AGENTS Direct Pilocarpine (generic) Pilocarpine 1%, 2%, 4% Increases trabecular outflow BID-QID/15-25% 15ml Headache, blurred vision, myopia, retinal detachment, bronchiole constriction, Angle closure, shortness of breath, retinal narrowing of angle detachment Indirect Phospholine Iodide (Pfizer) Echothiophate iodide 0.125% Increases trabecular outflow QD-BID/15-25% 5ml Same as above plus cataractogenic iris cysts in children, pupillary block, Same as above, plus avoid prior to any increased paralysis with succinylcholine general anesthetic procedure ALPHA-2 AGONISTS Alphagan P (Allergan) Brimonidine tartrate 0.1%, 0.15% with Purite Decreases aqueous production, increases BID-TID/up to 26% 5ml, 10ml, 15ml Dry mouth, hypotension, bradycardia, follicular conjunctivitis, ocular irritation, Monitor for shortness of breath, dizziness, preservative uveoscleral outflow pruritus, dermatitis, conjunctival blanching, eyelid retraction, mydriasis, drug ocular redness and itching, fatigue allergy Brimonidine tartrate Brimonidine tartrate 0.15%, 0.2% Same as above Same as above 5ml, 10ml Same as above Same as above (generic) Iopidine (Novartis) Apraclonidine 0.5% Decreases aqueous production BID-TID/up to 25% 5ml, 10ml Same as above but higher drug allergy (40%) Same as above BETA-BLOCKERS Non-selective Betagan (Allergan) Levobunolol 0.25%, 0.5% Decreases
    [Show full text]
  • Rhopressa™ Netarsudil Ophthalmic Solution 0.02%
    Rhopressa™ Netarsudil ophthalmic solution 0.02% CDER Dermatologic and Ophthalmic Drugs Advisory Committee October 13, 2017 Aerie Pharmaceuticals, Inc. 1 Introduction Marvin Garrett Vice President, Regulatory Affairs and Quality Assurance Aerie Pharmaceuticals, Inc. 2 Aerie Pharmaceuticals • 2005: Aerie founded as a spin-out from Duke University: – Dr. Eric Toone – Dr. Casey Kopczynski – Dr. David Epstein – Dr. Epstein’s goal from the beginning: Develop a therapy that targeted the diseased tissue in glaucoma, the trabecular outflow pathway • 2006: Aerie discovered its first Rho kinase inhibitor • 2009: Aerie invented netarsudil • 2012: Netarsudil 1st clinical study • 2017: NDA filed 3 Netarsudil: A New Drug Class for Lowering IOP We are requesting a recommendation for approval of netarsudil ophthalmic solution 0.02% for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension given one drop QD 4 Agenda Unmet Medical Needs Richard A. Lewis, MD Chief Medical Officer Aerie Pharmaceuticals, Inc. Past President, American Glaucoma Society Program Design and Efficacy Casey Kopczynski, PhD Chief Scientific Officer Aerie Pharmaceuticals, Inc. Safety Theresa Heah, MD, MBA VP Clinical Research and Medical Affairs Aerie Pharmaceuticals, Inc. Benefits and Risks Janet Serle, MD Professor of Ophthalmology Glaucoma Fellowship Director Icahn School of Medicine at Mount Sinai 5 List of Expert Responders • Cynthia Mattox, MD – Associate Professor of Ophthalmology, Tufts University School of Medicine – Current President, American Glaucoma Society • Mark Reasor, PhD – Professor of Physiology & Pharmacology, Robert C. Byrd Health Sciences Center, West Virginia University • Bennie H. Jeng, MD – Professor and Chair, Department of Ophthalmology & Visual Sciences, University of Maryland School of Medicine • Dale Usner, PhD – Biostatistics Consultant to Aerie Pharmaceuticals, Inc.
    [Show full text]
  • Exceptional Longevity and Potential Determinants Of
    Adams et al. Acta Vet Scand (2016) 58:29 DOI 10.1186/s13028-016-0206-7 Acta Veterinaria Scandinavica RESEARCH Open Access Exceptional longevity and potential determinants of successful ageing in a cohort of 39 Labrador retrievers: results of a prospective longitudinal study Vicki Jean Adams1*, Penny Watson2, Stuart Carmichael3, Stephen Gerry4, Johanna Penell5 and David Mark Morgan6 Abstract Background: The aim of this study was to describe the longevity and causes of mortality in 39 (12 males, 27 females) pedigree adult neutered Labrador retrievers with a median age of 6.5 years at the start of the study and kept under similar housing and management conditions. Body condition score was maintained between two and four on a 5-point scale by varying food allowances quarterly. The impact of change in body weight (BW) and body composition on longevity was analysed using linear mixed models with random slopes and intercepts. Results: On 31 July 2014, 10 years after study start, dogs were classified into three lifespan groups: 13 (33 %) Expected ( 9 to 12.9 years), 15 (39 %) Long ( 13 to 15.5 years) and 11 (28 %) Exceptional ( 15.6 years) with five still alive.≥ Gender≤ and age at neutering were≥ not associated≤ with longevity (P 0.06). BW increased≥ similarly for all lifespan groups up to age 9, thereafter, from 9 to 13 years, Exceptional dogs gained≥ and Long-lifespan dogs lost weight (P 0.007). Dual-energy x-ray absorptiometer scans revealed that absolute fat mass increase was slower to age 13 for =Long compared with Expected lifespan dogs (P 0.003) whilst all groups lost a similar amount of absolute lean mass (P > 0.05).
    [Show full text]
  • Dog Breeds of the World
    Dog Breeds of the World Get your own copy of this book Visit: www.plexidors.com Call: 800-283-8045 Written by: Maria Sadowski PlexiDor Performance Pet Doors 4523 30th St West #E502 Bradenton, FL 34207 http://www.plexidors.com Dog Breeds of the World is written by Maria Sadowski Copyright @2015 by PlexiDor Performance Pet Doors Published in the United States of America August 2015 All rights reserved. No portion of this book may be reproduced or transmitted in any form or by any electronic or mechanical means, including photocopying, recording, or by any information retrieval and storage system without permission from PlexiDor Performance Pet Doors. Stock images from canstockphoto.com, istockphoto.com, and dreamstime.com Dog Breeds of the World It isn’t possible to put an exact number on the Does breed matter? dog breeds of the world, because many varieties can be recognized by one breed registration The breed matters to a certain extent. Many group but not by another. The World Canine people believe that dog breeds mostly have an Organization is the largest internationally impact on the outside of the dog, but through the accepted registry of dog breeds, and they have ages breeds have been created based on wanted more than 340 breeds. behaviors such as hunting and herding. Dog breeds aren’t scientifical classifications; they’re It is important to pick a dog that fits the family’s groupings based on similar characteristics of lifestyle. If you want a dog with a special look but appearance and behavior. Some breeds have the breed characterics seem difficult to handle you existed for thousands of years, and others are fairly might want to look for a mixed breed dog.
    [Show full text]
  • Nutritional and Herbal Supplements in the Treatment of Obsessive Compulsive Disorder
    Open access Review Gen Psych: first published as 10.1136/gpsych-2019-100159 on 11 March 2020. Downloaded from Nutritional and herbal supplements in the treatment of obsessive compulsive disorder Canan Kuygun Karcı ,1 Gonca Gül Celik2 To cite: Kuygun Karcı C, Gül ABSTRACT pharmacotherapy with selective serotonin Celik G. Nutritional and herbal Obsessive- compulsive disorder (OCD) is a neuropsychiatric reuptake inhibitors (SSRI), the tricyclic supplements in the treatment disorder that is characterised by obsessions and antidepressant clomipramine, or serotonin of obsessive compulsive compulsions. The recommended treatments for OCD disorder. General Psychiatry noradrenaline reuptake inhibitors such as are cognitive– behavioural therapy using exposure and 8 9 2020;33:e100159. doi:10.1136/ venlafaxine or duloxetine. response prevention and/or pharmacotherapy. On the other gpsych-2019-100159 Limited effectiveness and possible side hand, some nutritional and herbal supplements may be effects of present treatments have lead to the Received 03 October 2019 effective in the treatment of OCD. Nutritional and herbal Revised 02 December 2019 supplements in OCD treatment will be reviewed in this search for alternative strategies. It is known Accepted 19 December 2019 paper. PubMed (Medline), Cochrane Library and Google that various nutritional deficiencies can Scholar databases were reviewed for the topic. There are be detected in patients with mental disor- some supplements that have been researched in OCD ders. Therefore, nutritional supplements treatment studies such as vitamin D, vitamin B12, folic are thought to be effective in treatment. acid, homocysteine, trace elements, N- acetyl cysteine, In this paper, use of nutritional and herbal glycine, myoinositol, St John’s wort, milk thistle, valerian supplements in the treatment of OCD will be root, curcumin and borage.
    [Show full text]
  • Looking for New Classes of Bronchodilators
    REVIEW BRONCHODILATORS The future of bronchodilation: looking for new classes of bronchodilators Mario Cazzola1, Paola Rogliani 1 and Maria Gabriella Matera2 Affiliations: 1Dept of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy. 2Dept of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy. Correspondence: Mario Cazzola, Dept of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome, 00133, Italy. E-mail: [email protected] @ERSpublications There is a real interest among researchers and the pharmaceutical industry in developing novel bronchodilators. There are several new opportunities; however, they are mostly in a preclinical phase. They could better optimise bronchodilation. http://bit.ly/2lW1q39 Cite this article as: Cazzola M, Rogliani P, Matera MG. The future of bronchodilation: looking for new classes of bronchodilators. Eur Respir Rev 2019; 28: 190095 [https://doi.org/10.1183/16000617.0095-2019]. ABSTRACT Available bronchodilators can satisfy many of the needs of patients suffering from airway disorders, but they often do not relieve symptoms and their long-term use raises safety concerns. Therefore, there is interest in developing new classes that could help to overcome the limits that characterise the existing classes. At least nine potential new classes of bronchodilators have been identified: 1) selective phosphodiesterase inhibitors; 2) bitter-taste receptor agonists; 3) E-prostanoid receptor 4 agonists; 4) Rho kinase inhibitors; 5) calcilytics; 6) agonists of peroxisome proliferator-activated receptor-γ; 7) agonists of relaxin receptor 1; 8) soluble guanylyl cyclase activators; and 9) pepducins. They are under consideration, but they are mostly in a preclinical phase and, consequently, we still do not know which classes will actually be developed for clinical use and whether it will be proven that a possible clinical benefit outweighs the impact of any adverse effect.
    [Show full text]
  • Localization of Metallothioneins-I & -II and -III in the Brain of Aged
    Localization of Metallothioneins-I & -II and -III in the Brain of Aged Dog Seiji KOJIMA, Akinori SHIMADA*, Takehito MORITA, Yoshiaki YAMANO1) and Takashi UMEMURA2) Departments of Veterinary Pathology and 1)Metabolic Biochemistry, Tottori University, Minami 4-101, Tottori-shi, Tottori 680-0945, and 2)Laboratory of Comparative Pathology, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo-shi, Hokkaido 060–0818, Japan (Received 2 November 1998/Accepted 7 December 1998) ABSTRACT. Localization of metallothionein (MT) -I & -II and MT-III and its significance in the brain aging in dogs were examined using immunohistological and molecular pathological techniques. MT-I & -II immunohistochemistry showed positive staining in the hypertrophic astrocytes throughout the aged dog brains; these MT-I & -II immunoreactive astrocytes were predominant in the cerebral cortex and around the blood vessels in the brain. These findings dominated in the brain regions with severe age-related morphological changes. In situ hybridization using MT-I mRNA riboprobes also demonstrated signals for MT-I mRNA in these hypertrophic astrocytes. Immunohistochemistry using a guinea pig antiserum against a synthetic polypeptide of canine MT-III demonstrated positive MT-III immunoreactivity predominantly in neurons in the Zn-rich regions such as hippocampus and parahippocampus. The findings were supported by in situ hybridization using MT-III mRNA riboprobes. Both MT-III immunoreactivity and signals for MT-III mRNA were demonstrated in neurons in the brain regardless of the intensity of the age-related changes. These results suggest, first, MT-I & -II may be induced in relation to the progress of the age-related morphological changes in the brain, playing an important role in the protection of the brain tissue from the toxic insults responsible for the brain aging, and second, MT-III may play a role in maintenance of Zn-related essential functions of the brain.—KEY WORDS: aging, brain, canine, in situ hybridization, metallothionein.
    [Show full text]
  • Behavioural and Cognitive Changes in Aged Pet Dogs: No Effects of an Enriched Diet and Lifelong Training
    PLOS ONE RESEARCH ARTICLE Behavioural and cognitive changes in aged pet dogs: No effects of an enriched diet and lifelong training 1,2 3,4 1,2 5 Durga ChapagainID *, Lisa J. Wallis , Friederike Range , Nadja Affenzeller , Jessica Serra6, Zso fia ViraÂnyi1 1 Clever Dog Lab, Comparative Cognition, Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University of Vienna, University of Vienna, Vienna, Austria, 2 Domestication Lab, Konrad Lorenz Institute of Ethology, University of Veterinary Medicine Vienna, Vienna, Austria, 3 Department of a1111111111 Livestock and One Health, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, a1111111111 Liverpool, United Kingdom, 4 Department of Ethology, EoÈtvoÈs LoraÂnd University, Budapest, Hungary, a1111111111 5 Department/Clinic for Companion Animals and Horses, University of Veterinary Medicine Vienna, Vienna, a1111111111 Austria, 6 Royal Canin Research Centre, Aimargues, France a1111111111 * [email protected] Abstract OPEN ACCESS Dogs demonstrate behavioural changes and cognitive decline during aging. Compared to Citation: Chapagain D, Wallis LJ, Range F, Affenzeller N, Serra J, ViraÂnyi Z (2020) Behavioural laboratory dogs, little is known about aging in pet dogs exposed to different environments and cognitive changes in aged pet dogs: No effects and nutrition. In this study, we examined the effects of age, an enriched diet and lifelong of an enriched diet and lifelong training. PLoS ONE training on different behavioural and cognitive measures in 119 pet dogs (>6yrs). Dogs were 15(9): e0238517. https://doi.org/10.1371/journal. pone.0238517 maintained on either an enriched diet or a control diet for one year. Lifelong training was cal- culated using a questionnaire where owners filled in their dog's training experiences to date.
    [Show full text]